Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

British Journal of Cancer

Volumn 92, Issue 10, 2005, Pages 1855-1861

  Awada, A ^a   Hendlisz, A ^a   Gil, T ^a   Bartholomeus, S ^a   Mano, M ^a   De Valeriola, D ^a   Strumberg, D ^b   Brendel, E ^c   Haase, C G ^c   Schwartz, B ^d   Piccart, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c BAYER PHARMA AG   (Germany)

^d BAYER CORPORATION   (United States)

Author keywords

BAY 43 9006; Efficacy; Pharmacokinetics; Safety; Solid tumours; Targeted agent

Indexed keywords

ANTINEOPLASTIC AGENT; SORAFENIB; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LIVER CANCER; LIVER TOXICITY; LUNG CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; OPEN STUDY; OVARY CANCER; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY NEUROPATHY; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME; DRUG ADMINISTRATION; KIDNEY CARCINOMA; KIDNEY TUMOR; MIDDLE AGED; NEOPLASM;

ADULT; AGED; BENZENESULFONATES; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRIDINES;

EID: 20344362911     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602584     Document Type: Article

References (19)

1. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF (2001) Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56: 127-155
2. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
4. Erhardt P, Schremser EJ, Cooper GM (1999) B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19: 5308-5315
5. Gianpaolo-Ostravage C, Carter C, Hibner B, Bankston D, Natero R, Monahan M C, Riedl B (2001) Anti-tumor efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumor xenograft models. Proc Am Assoc Cancer Res 42: 923
6. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D (1995) Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270: 25915-25919
7. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822
8. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R, Pritchard C (2001) MEK kinase activity is not necessary for Raf-1 function. EMBO J 20: 1940-1951
9. Kerkhoff E, Rapp UR (1997) Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol Cell Biol 17: 2576-2586
10. Lyons JF, Wilhelm S, Hibner B, Bollag G (2001) Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8: 219-225
11. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934
12. Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J (2001) Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 15: 981-994
13. Strumberg D, Awada A, Piccart P, Hirte H, Moore M, Clark J, Lenz H-J, Lathia C, Schwartz B, Humphrey R (2003) Final report of the multiple single agent phase I clinical trials of the novel Raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 22, (abstract 813)
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
15. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47: 13-47
16. Wang HG, Rapp UR, Reed JC (1996) Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87: 629-638
17. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109
18. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR, Zimmer A (1997) Endothelial apoptosis in Braf-deficient mice. Nat Genet 16: 293-297
19. Zhong J, Troppmair J, Rapp UR (2001) Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria. Oncogene 20: 4807-4816